A new report by Unleash Prosperity calls for a major overhaul of the FDA's drug approval process to cut lengthy effectiveness reviews, which delay patient access to lifesaving medicines. Economist Tomas Philipson highlights that most delays are due to effectiveness trials rather than safety concerns. The report estimates that reducing approval times by just one year could generate over $10 trillion in economic value, accelerate innovation, and lower prescription drug costs by increasing competition. It also warns that faster, cheaper clinical trials in China could draw investment away from the U.S., urging policymakers to adopt reforms like AI use in reviews and faster trial designs, similar to the COVID-era Operation Warp Speed initiative.
The global password management market, valued at $5.55 billion in 2025, is projected to grow to $42.21 billion by 2035, driven by increasing cyberattacks, data breaches, and the rise of remote work. Enterprises are adopting advanced password solution...
Despite high public enthusiasm for AI investments, many top insiders like Stanley Druckenmiller, Peter Thiel, and Michael Burry are selling or betting against AI stocks. This insider selling, often a signal of caution, contrasts with the booming mark...
Circle's stock rebounded 6.88% to $73.57 amid strong growth in USDC supply and transaction volume, which rose 28% and 263% year-over-year respectively. The company is expanding USDC distribution through partnerships in emerging markets and integratin...
Bloom Energy is rated a Strong Buy due to rising demand for AI-driven data center power and rapid contract wins with major cloud providers. Its flexible solid oxide fuel cell (SOFC) technology supports a 140% increase in backlog and a raised revenue ...
Korn Ferry's Q4 2026 results confirm improving earnings driven by strong fee revenue growth and robust performance in its Search and Professional Search & Interim segments. The company achieved higher pricing, margin expansion, and quality growth, de...
